ABIONYX Pharma S.A.

ABNX.PA

Biotechnology · Healthcare

Price

€1.95

-0.04 (-1.91%)

Market Cap

€82.6M

Exchange

Euronext Paris

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Dec 31, 2025

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Mixed

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+42.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 24.9M (2021) → 35.5M (2025)

Winston Score History

The full picture

ABIONYX Pharma is a small French biotechnology company focused on developing medicines for serious diseases related to inflammation and the kidneys. Its main technology is based on a synthetic version of a natural protein called ApoA-I, which plays a role in managing cholesterol and reducing inflammation in the body. The company's lead experimental drug, CER-001, is being tested in patients with conditions like nephrotic syndrome, a kidney disorder with few good treatment options today.

ABIONYX does not yet sell any approved products, so it currently earns little to no revenue from product sales. It is based in France and operates at a significant loss, which is typical for early-stage biotech companies that spend heavily on clinical trials before generating income. The company's future depends almost entirely on whether its drug candidates succeed in clinical trials and eventually receive regulatory approval — failure in trials would be a serious risk to the business.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-13.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-37.5% YoY

YoY Growth Rate

Earnings declining

R&D Spend

€2M/ year

↓ Declining (-50% vs prior year)

36.9% of revenue

2.1x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

4.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~8 months

€4M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

ABIONYX Pharma S.A. has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

9.6%

Thin — 9.6% gross margin

Profit after running costs

Operating Margin

-201.9%

Losing money on operations — -201.9%

Return on the money invested

ROCE

-93.7%

Weak — -93.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-11.7%

Shrinking sales (-11.7% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-78.2%

Burning cash (-78.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.57

Conservative — low debt load (0.57)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial